Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA-4 in Crohn's disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 5, 2011, Pages 924-930

  Chen, Zhitao ^a,b   Zhou, Feng ^a   Huang, Sha ^a   Jiang, Ting ^a,b   Chen, Liping ^a   Ge, Liuqing ^a   Xia, Bing ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Wuhan Central Hospital   (China)

Author keywords

(AT)n repeats; Crohn's disease; Cytotoxic T lymphocyte associated antigen 4; Polymorphism

Indexed keywords

C REACTIVE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CHINA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK;

EID: 79954538338     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06662.x     Document Type: Article

References (37)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-34.
2. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J. Immunol. 2006; 177: 1052-61.
3. Waterhouse P, Penninger JM, Timms E etal. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-8.
4. Ying H, Yang L, Qiao G etal. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J. Immunol. 2010; 185: 1375-8.
5. Hölttä V, Klemetti P, Sipponen T etal. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm. Bowel Dis. 2008; 14: 1175-84.
6. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell. Immunol. 2000; 201: 144-53.
7. Saverino D, Brizzolara R, Simone R etal. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin. Immunol. 2007; 123: 190-8.
8. Simone R, Brizzolara R, Chiappori A etal. A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. Int. Immunol. 2009; 21: 1037-45.
9. Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 2005; 44: 989-94.
10. Toussirot E, Saas P, Deschamps M etal. Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Res. Ther. 2009; 11: R101.
11. Shi HZ, Mo XY, Zhong XN. Soluble CTLA-4 in sera of patients with bronchial asthma. J. Asthma 2005; 42: 133-9.
12. Wang XB, Kakoulidou M, Giscombe R etal. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neuroimmunol. 2002; 130: 224-32.
13. Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol. Rev. 2008; 223: 143-55.
14. Zhao SX, Pan CM, Cao HM etal. Association of the CTLA4 gene with Graves' disease in the Chinese Han population. PLoS ONE 2010; 5: e9821.
15. Malquori L, Carsetti L, Ruberti G. The 3′ UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency. Biochim. Biophys. Acta. 2008; 1779: 60-5.
16. Takara M, Kouki T, DeGroot LJ. CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves' disease. Thyroid 2003; 13: 1083-9.
17. Park KS, Baek JA, Do JE, Bang D, Lee ES. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet's disease. Tissue Antigens 2009; 74: 222-7.
18. Wang XB, Pirskanen R, Giscombe R, Lefvert AK. Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J. Intern. Med. 2008; 263: 61-9.
19. Chistiakov DA, Savost'anov KV, Turakulov RI, Efremov IA, Demurov LM. Genetic analysis and functional evaluation of the C/T(-318) and A/G(-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves' disease. Clin. Immunol. 2006; 118: 233-42.
20. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 1989; 170: 2-6.
21. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
22. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
23. Chen PL, Fann CS, Chang CC etal. Family-based association study of cytotoxic T-lymphocyte antigen-4 with susceptibility to Graves' disease in Han population of Taiwan. Genes Immun. 2008; 9: 87-92.
24. Kusztal M, Kościelska-Kasprzak K, Drulis-Fajdasz D etal. The influence of CTLA-4 gene polymorphism on long-term kidney allograft function in Caucasian recipients. Transpl. Immunol. 2010; 23: 121-4.
25. Hudson LL, Rocca K, Song YW, Pandey JP. CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum. Genet. 2002; 111: 452-5.
26. Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI etal. Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflamm. Bowel Dis. 2010; [Epub ahead of print] PMID: 20629092; DOI: 10.1002/ibd.21410.
27. Jiang Y, Xia B, Jiang L etal. Association of CTLA-4 gene microsatellite polymorphism with ulcerative colitis in Chinese patients. Inflamm. Bowel Dis. 2006; 12: 369-73.
28. Huang D, Giscombe R, Zhou Y, Lefvert AK. Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J. Rheumatol. 2000; 27: 397-401.
29. Huang D, Liu L, Norén K etal. Genetic association of Ctla-4 to myasthenia gravis with thymoma. J. Neuroimmunol. 1998; 88: 192-8.
30. Zhou Y, Huang D, Paris PL, Sauter CS, Prock KA, Hoffman GS. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum. 2004; 50: 2645-50.
31. Rodríguez MR, Núñez-Roldán A, Aguilar F, Valenzuela A, García A, González-Escribano MF. Association of the CTLA4 3′ untranslated region polymorphism with the susceptibility to rheumatoid arthritis. Hum. Immunol. 2002; 63: 76-81.
32. Ihara K, Ahmed S, Nakao F etal. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with type 1 diabetes in the Japanese population. Immunogenetics 2001; 53: 447-54.
33. Machida H, Tsukamoto K, Wen CY etal. Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J. Gastroenterol. 2005; 11: 4188-93.
34. Pistillo MP, Tazzari PL, Bonifazi F etal. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. Transplantation 2002; 73: 1295-302.
35. Nagaraju K, Raben N, Villalba ML etal. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin. Immunol. 1999; 92: 161-9.
36. Berry A, Tector M, Oaks MK. Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms. J. Negat. Results Biomed. 2008; 7: 8.
37. Kaartinen T, Lappalainen J, Haimila K, Autero M, Partanen J. Genetic variation in ICOS regulates mRNA levels of ICOS and splicing isoforms of CTLA4. Mol. Immunol. 2007; 44: 1644-51.